Life Sciences Firm Advances Massive US$2.4B Market Opportunity

1. BioLargo Inc. is a billboard sponsor of Streetwise Reports and pays SWR a monthly sponsorship fee between US$3,000 and US$6,000.
2. As of the date of this article, officers, contractors, shareholders, and/or employees of Streetwise Reports LLC (including members of their household) own securities of BioLargo Inc.
3. Steve Sobek wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
4. This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company. 
5. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

1. Disclosure for the quote from the John Newell article published on March 3, 2026

1. For the quoted article (published on March 3, 2026), the Company has paid Street Smart, an affiliate of Streetwise Reports, US$2,550.
2. Author Certification and Compensation: [John Newell of John Newell and Associates] was retained and compensated as an independent contractor by Street Smart for writing this article. Mr. Newell holds a Chartered Investment Management (CIM) designation (2015) and a  U.S. Portfolio Manager designation (2015). The recommendations and opinions expressed in this content reflect the personal, independent, and objective views of the author regarding any and all of the companies discussed. No part of the compensation received by the author was, is, or will be directly or indirectly tied to the specific recommendations or views expressed.

John Newell Disclaimer

As always it is important to note that investing in precious metals like silver carries risks, and market conditions can change violently with shock and awe tactics, that we have seen over the past 20 years. Before making any investment decisions, it's advisable consult with a financial advisor if needed. Also the practice of conducting thorough research and to consider your investment goals and risk tolerance.

2. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

Positive clinical experiences with ViaCLYR™, an advanced wound irrigation solution from Clyra Medical Technologies, were presented by Dr. Marcus Gitterle at the Boswick Symposium in Maui, Hawaii, on January 28, according to a February 18 release from clean tech company BioLargo Inc. (BLGO:OTCQX).

Gitterle, a prominent figure in wound care and Regional Medical Director for Wound Care and Hyperbaric Oxygen Therapy at Christus Santa Rosa Hospital System in San Antonio, Texas, shared results from a multi-site evaluation involving about 36 cases across four wound clinics over four months.

The presentation highlighted outcomes in challenging wound care scenarios, such as diabetic foot ulcers, venous leg ulcers, pressure injuries, and complex surgical wounds. Gitterle described the results as "remarkable" and "unusual," noting ViaCLYR™'s excellent safety, strong antimicrobial performance, and enhanced healing characteristics. Importantly, no adverse reactions were reported during the evaluation, underscoring ViaCLYR™'s favorable safety and tolerability profile.

"In our multi-site clinical experience involving approximately 36 cases across diverse wound etiologies, ViaCLYR™ demonstrated clinically significant improvements in several wound characteristics, including enhanced granulation velocity, rapid sinus tract closure, and notable drainage reduction," Gitterle said. "Patients with chronic, fibrotic wounds showed rapid transformation to highly proliferative healing wounds, characteristics I found quite unusual given the severity of underlying disease and chronicity. Importantly, we observed no adverse events in our treatment population. The tissue effects we observed are likely related not only to very effective long-duration wound cleansing and biofilm suppression, but also to the beneficial effects of copper on healing processes."

The doctor continued, "Because of the success of this evaluation, we are moving as a group to adoption of CICS as our wound care cleansing modality of choice."

ViaCLYR™ employs Clyra's proprietary Copper-Iodine Complex Solution (CICS), known as Clyrasept™, which offers rapid, broad-spectrum antimicrobial activity while remaining biocompatible. Key clinical observations included:

• Rapid reduction in wound fluid discharge.
• Noticeable increase in healing activity early in treatment, with improved tissue quality.
• Rapid closure or shortening of wound tunnels.
• Improved wound edge appearance and new skin formation.
• Dramatic transformation of chronic, scarred wounds to actively healing wounds.
• Significant wound shrinkage and reduction in wound depth, particularly in pressure injuries.

According to Clyra Medical Technologies Chief Executive Officer Steve Harrison, the clinical experiences shared at the symposium underscore what ViaCLYR™ was designed to achieve: effective antimicrobial support that works with the body, not against it.

"Having an independent clinician of Dr. Gitterle's stature describe real-world performance that exceeds expectations, presented to a highly respected audience of wound care specialists, represents important validation as we continue our commercial rollout," he said.

A Respected Platform for Advancing Wound Care Knowledge

Gitterle's presentation offered insights into the scientific principles behind the copper-iodine complex technology, which has been the focus of ongoing research and clinical evaluation in wound care settings, BioLargo said in the release.

The Boswick Symposium serves as a respected platform for advancing wound care knowledge, bringing together leading clinicians, researchers, and innovators dedicated to improving outcomes in complex wound management. The clinical insights shared at the conference contribute to a broader understanding and evaluation of emerging technologies in real-world care environments.

"Hearing clinicians describe transformative clinical outcomes (such as) wounds transitioning from chronic and fibrotic to highly proliferative in remarkably short timeframes is exactly what drives adoption in wound care," said Dennis P. Calvert, Clyra chairman and BioLargo's CEO. "Dr. Gitterle's presentation reinforces the promise of Clyra's technology as we expand access to ViaCLYR™ and support the clinical community with evidence-based solutions."

Clyra Medical Technologies said it remains committed to supporting ongoing clinical evaluations and plans additional presentations and publications throughout 2026 as part of its dedication to evidence-based adoption and clinician education.

Start of Commercial Distribution Reached

Earlier in February, BioLargo announced that Clyra received its first commercial stocking order from Advanced Solution LLC for ViaCLYR™, marking the start of commercial distribution and signifying Clyra's transition from development-stage operations to generating initial revenue. The stocking order ensures product availability through Advanced Solution's national distribution network, facilitating sales to hospitals, clinics, and healthcare providers across the United States. BioLargo views this milestone as the first in a series of planned commercial and revenue-related announcements as Clyra advances its market rollout.

"This initial commercial order reflects years of disciplined development, regulatory execution, and commercial preparation," Harrison said at the time. "With ViaCLYR™ now entering the distribution channel, we are beginning the transition from innovation to execution, laying the groundwork for scalable revenue growth as adoption expands."

ViaCLYR™ is a highly effective, tissue-safe, long-acting wound irrigation solution suitable for acute and chronic wounds and burns. This unique, clear, odorless, non-irritating solution is 510(k) cleared by the FDA and indicated for acute and chronic wounds. It boasts extremely high antimicrobial activity as a preservative in solution, with over 99.9999% kill rate (up to 7 log reduction) and sustained efficacy for up to 72 hours, the company said.

Clyra is a partially owned subsidiary of BioLargo that focuses on infection control and advanced wound care. Founded in 2012, the company develops and commercializes wound care solutions based on its proprietary Copper-Iodine Complex Technology. Clyra's product portfolio features FDA-cleared medical devices that leverage this patented technology to deliver superior wound care outcomes.

Analyst: Clyra Is Gaining Attention

¹According to Technical Analyst John Newell of John Newell & Associates, writing for Streetwise Reports on March 11, BioLargo is making strides in addressing critical healthcare and environmental challenges through its diverse technology platforms.

Its Clyra technology is gaining attention in the healthcare sector for its ability to effectively eliminate pathogens without harming human tissue, making it a promising tool in the fight against hospital-acquired infections and antibiotic resistance, he said.

BioLargo operates as a technology incubator, advancing its proprietary technologies through scientific validation and partnering with established organizations to scale these innovations, Newell noted. Its portfolio includes solutions for advanced water treatment, environmental remediation, odor and air quality control, long-duration energy storage, and medical technologies. Among these, Clyra Medical Technologies stands out with its copper-iodine antimicrobial solutions that maintain effectiveness for up to 72 hours without causing cytotoxic damage, a significant advantage in treating wounds and surgical infections.

Clyra's lead product, ViaCLYR, has received FDA 510(k) clearance, facilitating its commercial distribution through established medical device channels. The technology, protected by around 40 issued and pending patents, offers various delivery formats such as liquids, powders, hydrogels, and antimicrobial dressings.

Clyra CEO Harrison emphasized the potential of this technology in healthcare settings, stating, "As the technology gains traction across hospitals and healthcare systems, Clyra Medical should emerge as a standalone healthcare company."

In addition to its medical innovations, BioLargo is developing a long-duration energy storage system, the Cellinity™ battery, designed to overcome the limitations of lithium-ion batteries in grid-scale applications. This system, built from earth-abundant materials, aims for multi-decade durability and is intended for licensing and partnership with manufacturing facilities.

BioLargo's leadership, guided by President and CEO Dennis P. Calvert and Clyra's CEO Steve Harrison, continues to drive the company's growth and innovation, Newell said.

BioLargo presents itself as a Speculative Buy, he said, offering multiple potential catalysts across its technology platforms. The company's strategic approach to commercialization and partnership positions it well to capitalize on the growing needs for advanced healthcare solutions and sustainable energy storage.

In 2025, BioLargo made significant strides in several project initiatives, "reflecting the company's shift from development to real-world application," according to Richard Ryan, an analyst at Oak Ridge Financial, in a research note dated January 5. Ryan rated the stock as a Buy.

Looking forward to this year, BioLargo expects to achieve validation of its technologies and Clyra's products, along with significant revenue from Clyra. According to Oak Ridge, in 2026, BioLargo and other small-cap stocks "may begin to reap the benefits of enhanced productivity from the AI trade and a sustained monetary easing cycle, thus narrowing the growing valuation gap."

The Catalyst: Infections Are a Serious Concern

The global market for anti-biofilm wound dressings is anticipated to grow at a compound annual growth rate (CAGR) of 9.8% from 2025 to 2035, rising from US$943.5 million to US$2.4 billion, Future Market Insights reported. This growth is primarily driven by the increasing incidence of surgical site infections, diabetic ulcers, and chronic wounds.

Biofilms, which contribute to antibiotic resistance and slow healing, are also a significant factor. In the U.S., the market is expected to expand significantly, with a projected CAGR of 9.3% over the period. This growth is supported by the prevalence of chronic wounds, an aging population, the demand for advanced care, technological advancements, and government initiatives, according to the research firm.

Fact.MR, a global provider of data-driven market intelligence, reported that "The global wound irrigation solution market is evaluated at a size of US$732 million in 2024 and has been forecasted to expand at a CAGR of 3.4% to reach US$1.02 billion by the end of 2034." The increasing prevalence of chronic diseases such as diabetes and vascular conditions is driving the demand for wound care solutions. Hospitals and clinics are increasingly adopting wound irrigation protocols to prevent surgical site infections.

According to the National Institutes of Health, approximately 99,000 deaths are associated with healthcare-associated infections (HAIs) each year. On any given day, about 1 in 31 hospital patients has at least one HAI. These infections are a serious concern, leading to millions of infections and significant costs for the healthcare system.

Ownership and Share Structure²

About 13.59% of BioLargo is owned by insiders and management. They include Chief Science Officer Kenneth Code with 8.03%, CEO Calvert with 3.27%, and Director Jack Strommen with 1.53%.

About 0.04% is held by the institution First American Trust. The rest, 86%, is retail.

Its market cap is US$54.2 million, with about 319.75 million shares outstanding and about 276.31 million free-floating. It trades in a 52-week range of US$0.30 and US$0.14.